NasdaqGM - Delayed Quote • USD
UroGen Pharma Ltd. (URGN)
At close: April 24 at 4:00 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 29,998 | 5 |
| Sales | 24,571 | 4 |
| Net Shares Purchased (Sold) | 5,427 | 9 |
| Total Insider Shares Held | 3.87M | -- |
| % Net Shares Purchased (Sold) | 0.10% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| SCHOENBERG MARK Officer | Sale at price 14.05 per share. | Direct | 168,600 | Mar 18, 2024 |
| SMITH JASON DREW General Counsel | Sale at price 15.78 per share. | Direct | 78,790 | Feb 1, 2024 |
| SCHOENBERG MARK Officer | Sale at price 15.74 per share. | Direct | 59,639 | Jan 31, 2024 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Jan 31, 2024 |
| SCHOENBERG MARK Officer | Sale at price 15.78 per share. | Direct | 59,790 | Jan 31, 2024 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Jan 31, 2024 |
| SMITH JASON DREW General Counsel | -- | Direct | -- | Jan 31, 2024 |
| KIM DONG Chief Financial Officer | -- | Direct | -- | Jan 31, 2024 |
| KIM DONG Chief Financial Officer | -- | Direct | -- | Jan 31, 2024 |
| SMITH JASON DREW General Counsel | Sale at price 18.01 per share. | Direct | 68,438 | Aug 31, 2023 |
| SMITH JASON DREW General Counsel | -- | Direct | -- | Aug 31, 2023 |
| COHEN FREDERICK E. M.D. PH.D. Director | Stock Award(Grant) at price 9.54 per share. | Indirect | 661,494 | Jul 26, 2023 |
| BARRETT ELIZABETH A Chief Executive Officer | -- | Direct | -- | Jan 31, 2023 |
| SCHOENBERG MARK Officer | Sale at price 10.12 per share. | Direct | 19,228 | Jan 31, 2023 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Jan 31, 2023 |
| SMITH JASON DREW General Counsel | Sale at price 10.12 per share. | Direct | 16,556 | Jan 31, 2023 |
| SMITH JASON DREW General Counsel | -- | Direct | -- | Jan 31, 2023 |
| SCHOENBERG MARK Officer | Conversion of Exercise of derivative security at price 5.00 per share. | Direct | 613,385 | Jan 20, 2023 |
| SCHOENBERG MARK Officer | Sale at price 11.85 per share. | Direct | 3,057 | Oct 31, 2022 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Oct 31, 2022 |
| NUSSBAUM RAN Director | Conversion of Exercise of derivative security at price 5.94 per share. | Indirect | 285,114 | Oct 21, 2022 |
| NUSSBAUM RAN Director | Conversion of Exercise of derivative security at price 5.94 per share. | Indirect | 285,114 | Oct 21, 2022 |
| BELLDEGRUN ARIE S Director | Conversion of Exercise of derivative security at price 5.00 per share. | Direct | 800,000 | Sep 14, 2022 |
| BELLDEGRUN ARIE S Director | Conversion of Exercise of derivative security at price 5.00 per share. | Direct | 16,205 | Aug 31, 2022 |
| SMITH JASON DREW General Counsel | Sale at price 7.21 per share. | Direct | 25,999 | Aug 31, 2022 |
| SMITH JASON DREW General Counsel | -- | Direct | -- | Aug 31, 2022 |
| SCHOENBERG MARK Officer | Sale at price 7.81 per share. | Direct | 2,023 | Aug 1, 2022 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Jul 29, 2022 |
| NUSSBAUM RAN Director | Conversion of Exercise of derivative security at price 5.00 per share. | Indirect | 11,055 | Jun 16, 2022 |
| NUSSBAUM RAN Director | Conversion of Exercise of derivative security at price 5.00 per share. | Indirect | 5,150 | Jun 6, 2022 |
| NUSSBAUM RAN Director | Conversion of Exercise of derivative security at price 5.00 per share. | Indirect | 5,150 | Jun 6, 2022 |
| SCHOENBERG MARK Officer | Sale at price 6.62 per share. | Direct | 1,681 | Apr 29, 2022 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Apr 29, 2022 |
| HENDERSON MOLLY Chief Financial Officer | Sale at price 7.58 per share. | Direct | 2,509 | Jan 31, 2022 |
| HENDERSON MOLLY Chief Financial Officer | -- | Direct | -- | Jan 31, 2022 |
| BARRETT ELIZABETH A Chief Executive Officer | Sale at price 7.58 per share. | Direct | 62,118 | Jan 31, 2022 |
| BARRETT ELIZABETH A Chief Executive Officer | -- | Direct | -- | Jan 31, 2022 |
| SCHOENBERG MARK Officer | Sale at price 7.58 per share. | Direct | 10,415 | Jan 31, 2022 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Jan 31, 2022 |
| SMITH JASON DREW General Counsel | Sale at price 7.58 per share. | Direct | 3,138 | Jan 31, 2022 |
| SMITH JASON DREW General Counsel | -- | Direct | -- | Jan 31, 2022 |
| SCHOENBERG MARK Officer | Sale at price 8.09 per share. | Direct | 898 | Jan 26, 2022 |
| SCHOENBERG MARK Officer | -- | Direct | -- | Jan 26, 2022 |
| BARRETT ELIZABETH A Chief Executive Officer | Sale at price 9.15 per share. | Direct | 429,757 | Jan 4, 2022 |
| BARRETT ELIZABETH A Chief Executive Officer | -- | Direct | -- | Jan 3, 2022 |
| HENDERSON MOLLY Chief Financial Officer | Sale at price 12.03 per share. | Direct | 31,122 | Nov 30, 2021 |
| HENDERSON MOLLY Chief Financial Officer | -- | Direct | -- | Nov 30, 2021 |
| SMITH JASON DREW General Counsel | Sale at price 12.03 per share. | Direct | 45,750 | Nov 30, 2021 |
| SMITH JASON DREW General Counsel | -- | Direct | -- | Nov 30, 2021 |
| SCHOENBERG MARK Officer | Purchase at price 13.10 per share. | Direct | 2,096 | Nov 18, 2021 |
Related Tickers
XENE Xenon Pharmaceuticals Inc.
39.50
-3.87%
ACRV Acrivon Therapeutics, Inc.
9.50
-3.26%
XNCR Xencor, Inc.
19.02
+3.54%
VRNA Verona Pharma plc
15.24
-2.25%
IGMS IGM Biosciences, Inc.
7.96
+3.38%
PTCT PTC Therapeutics, Inc.
25.21
-0.79%
ZNTL Zentalis Pharmaceuticals, Inc.
11.77
-6.36%
FHTX Foghorn Therapeutics Inc.
5.21
+0.97%
CGON CG Oncology, Inc.
36.05
-0.72%
TRDA Entrada Therapeutics, Inc.
12.43
-3.57%